Current medications: A list of other medications being taken, to ensure there are no interactions and that the GLP-1 therapy is the most appropriate option
These results indicate a dose-dependent response where the body adjusts gradually over a structured titration schedule, typically expressed in mg per week
#DDW2025 OBESITY AND IBD by @EdwardLoftus2 Obesity is a chronic inflammatory statue Adipose tissue is not biologically inert (TNFa, IL-6, IL-8, leptin, adiponectin) Postulated role in the pathogenesis of IBD Potential risk factor for adverse outcomes Trends in BMI among IBD patients at diagnosis in Olmsted County, Doubling of obesity rates in 20 years in CD and UC (Johnson AM JCC 2021 and J Clin Gastro 2024) Obese patients more likely to have a colonic phenotype
Focus on regulated, clinician-led options that are already available
If you are looking for broader education on GLP-1 care, our article on what GLP-1 support is and how it fits into weight loss is a helpful companion read
Patients with type 2 diabetes have an approximately two-fold risk for acute pancreatitis and a label indicating an acute pancreatitis risk has been added to all DPP-4 inhibitors
/assets/images/provider/photos/2826746.png)
